Mark Hollywood has been promoted to Executive Vice President and COO with expanded responsibilities beyond his current leadership of Technology and Manufacturing Operations, Quality, and Alliance/Program Management. Dr. Sabeen Mekan has been promoted to Senior Vice President and Chief Medical Officer effective February 1, with overall responsibility for clinical development, regulatory affairs, pharmacovigilance/patient safety, and clinical operations. Dr. Jeff Smith, current CMO, will be retiring effective January 31, while continuing to provide services as an adviser for a transitional time period. Leone Patterson, Chief Financial and Business Officer and Daniel Dex, General Counsel, will both be departing from their roles at Zymeworks (ZYME) during the first quarter of 2026. The company has commenced a comprehensive search for a permanent CFO with the experience required to support the company’s next phase of development. Galbraith has assumed the role of Acting CFO until a replacement is secured.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks outlines priorities, outlook for 2026
- Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth
- Zymeworks (ZYME): Zanidatamab’s Strong Phase 3 HERIZON-GEA Data, Global Milestones, and Royalty Model Support Buy Rating
- Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint of PFS